Search

Borderless careers

Start enriching your professional journey with EHA todayAdvance your career at any stage with the European Hematology Association.

The SWG on Pediatric Hematology has several key goals for the next four years (2024–2026):

To further develop our role as the voice of pediatric hematology within EHA
To reach out to YEHA pediatric hematologists to develop educational material to underpin our…

Red Cells and Iron

This SWG covers the clinical areas of inherited and acquired disorders of the erythrocyte and iron metabolism.

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers

Oct 26 2017

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.

Announcement: The award winners of the prestigious EHA-ASH Translational Research in Hematology Training Award are selected

Nov 25 2014 Posted in Press releases

The winners of the TRTH 2015 Awards are:

Name

Nationality

Name

Nationality

Ileana Antony-Debre

French

Jean-Baptiste Micol

French

Pavan Bachireddy

American

Christopher Ott

American

Lucile Couronné

French

Carsten Riether

German

Moniek de Witte

Dutch

Anindita Roy

British

Ammon Fager

American

Melody Smith

American

Gillian Horne

British

Zuzana Tothova

Slovakian

Moonjung Jung

South Korea

Marcin Wlodarski

Polish

Jonas Samuel Jutzi

Swiss - German

Yuh-Ying Yeh

Taiwanese

Milka Koupenova-Zamor

American - Bulgarian

Sasan Zandi

Iranian

Marwan Kwok

British

Patricia Maiso

Spain

Are you interested in joining the…

EHA Ranking 2025

The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version

Position
Company
Priority points
Corporate Level

1
Johnson & Johnson 
1. 488,82 
Platinum 

2
Bristol Myers Squibb 
1.

Chairs and Members

Chair (re-appointment, 2023–2026)Josef Vormoor—Professor of Hematological Malignancies in Children, University Medical Center Utrecht (The Netherlands)

Co-chair (re-appointment, 2023–2026)Maria Ester Bernardo—Clinical Coordinator, Clinical Research Unit, San Raffaele Telethon Institute for Gene Therapy (Italy)

SWG Steering Committee members (2024–2027 term)
SWG Secretary—Francesco Saglio, AOU Città…

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

Jun 13 2014 Posted in Press releases

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Jun 13 2014 Posted in Press releases

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.